This research aims to investigate the association between hyperthyroidism and age, sex, and infraction of the myocardium in the Hong Kong population to detect hyperthyroidism-induced infraction earlier (e.g., thyrocardiac disease) through chemiluminescent microparticle immunoassay (CMIA). A total of 7616 random blood specimens from males and females were collected and examined by Architect i immunoassay platform to obtain quantitative laboratory values of Free FT4, TSH, and hs-cTnI in samples serum differentiating into overt and subclinical hyperthyroidism cases. The age was between 19 and 81 years old. In this research, for population characteristics, 57 cases confirmed as hyperthyroidism (e.g. FT4 > 1.48 ng/dL, according to Abbott's suggested reference interval) were used for analysis and 22 cases were examined in the laboratory. The highest number of hyperthyroidism, including overt and subclinical cases in females, was 43 (75.44%), rather than males. For prevalence data of hyperthyroidism between September 2019 to January 2020 in Hong Kong, the range was from 0.62% to 0.93% (Median percentage = 0.75%). The research will explore the in-depth impact of gender differences on thyrocardiac disease, the risk of thyrocardiac disease by age group, and the possible relationship between FT4 and hs-cTnI.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of PHC Medical Diagnostic Centre Ltd. gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present work are contained in the manuscript